Trial Profile

Phase III trial of Melacine plus interferon alfa-2b versus interferon alfa-2b in patients with disseminated malignant melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Melanoma vaccine Melacine (Primary) ; Interferon alpha-2b
Indications Malignant melanoma
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Corixa Corporation; GlaxoSmithKline; GSK; Ribi ImmunoChem Research

Most Recent Events

27 Dec 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com